Andrew Morrison is Of Counsel in the London office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on a broad range of UK and European competition law matters. Andrew’s experience includes advising clients on complex multi-jurisdictional mergers, cartel investigations (including leniency and immunity), and abuse of dominance cases before UK and European authorities. He also represents clients in both UK and European appellate proceedings, as well as UK competition law damages proceedings.
Andrew has significant experience in the life sciences and healthcare sector, having worked on a wide variety of merger control matters for pharmaceuticals and medical device manufacturers, as well as on many of the UK and EU’s headline pharmaceutical investigations. In addition, he has extensive experience in retail and consumer goods, having spent a year on secondment advising on global antitrust and compliance matters for one of the UK’s largest listed global food and manufacturing conglomerates.
More broadly, Andrew has worked on major mandates in travel technology, aviation infrastructure, financial services, basic industries, logistics, and social care. He has also worked with a range of institutional investors to mitigate regulatory risk across their investment portfolios.
Andrew Morrison is Of Counsel in the London office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on a broad range of UK and European competition law matters. Andrew’s experience includes advising clients on complex multi-jurisdictional mergers, cartel investigations (including leniency and immunity), and abuse of dominance cases before UK and European authorities. He also represents clients in both UK and European appellate proceedings, as well as UK competition law damages proceedings.
Andrew has significant experience in the life sciences and healthcare sector, having worked on a wide variety of merger control matters for pharmaceuticals and medical device manufacturers, as well as on many of the UK and EU’s headline pharmaceutical investigations. In addition, he has extensive experience in retail and consumer goods, having spent a year on secondment advising on global antitrust and compliance matters for one of the UK’s largest listed global food and manufacturing conglomerates.
More broadly, Andrew has worked on major mandates in travel technology, aviation infrastructure, financial services, basic industries, logistics, and social care. He has also worked with a range of institutional investors to mitigate regulatory risk across their investment portfolios.
- Postgraduate Diploma in EU Competition Law, King's College London, 2018
- Legal Practice Course (LPC), BPP University, London, 2013
- Postgraduate Diploma in Law (GDL), BPP University, London, 2011
- M.Biochem (Hons), Biochemistry, University of Oxford, 2010
- Solicitor, England and Wales
- Postgraduate Diploma in EU Competition Law, King's College London, 2018
- Legal Practice Course (LPC), BPP University, London, 2013
- Postgraduate Diploma in Law (GDL), BPP University, London, 2011
- M.Biochem (Hons), Biochemistry, University of Oxford, 2010
- Solicitor, England and Wales
Select Matters
- Advised Teva Pharmaceuticals in relation to the UK Competition and Markets Authority’s (CMA’s) investigations into the conduct of its subsidiaries concerning the sale of hydrocortisone tablets in the UK*
- Advised Mylan in relation to the European Commission’s perindopril investigation*
- Advised Mylan in relation to the CMA’s paroxetine investigation and the subsequent appeal*
- Advised Flynn Pharma in relation to the CMA’s phenytoin abuse of dominance investigation*
- Advised Jazz Pharmaceuticals on its acquisition of GW Pharmaceuticals*
- Advised NuVasive on the UK merger control aspects of its acquisition by Globus*
- Advised Farelogix Inc. on its proposed acquisition by Farelogix and subsequent successful acquisition by Accelya*
- Advised Amcor on its acquisition of Bemis*
- Advised Associated British Foods Plc on the acquisition by its subsidiary, Jordans & Ryvita Company Limited, of Dorset Cereals*
- Advised CAA on its acquisition of ICM Partners*
- Advised ZF Friedrichshafen on the UK aspects of a number of strategic European joint ventures*
- Advised Daimler Truck and Volvo on the UK merger control aspects of the formation of Coretura*
- Advised a UK freight logistics company in relation to both general competition law compliance and a number of key strategic initiatives*
* Denotes matters prior to joining Wilson Sonsini.
Select Matters
- Advised Teva Pharmaceuticals in relation to the UK Competition and Markets Authority’s (CMA’s) investigations into the conduct of its subsidiaries concerning the sale of hydrocortisone tablets in the UK*
- Advised Mylan in relation to the European Commission’s perindopril investigation*
- Advised Mylan in relation to the CMA’s paroxetine investigation and the subsequent appeal*
- Advised Flynn Pharma in relation to the CMA’s phenytoin abuse of dominance investigation*
- Advised Jazz Pharmaceuticals on its acquisition of GW Pharmaceuticals*
- Advised NuVasive on the UK merger control aspects of its acquisition by Globus*
- Advised Farelogix Inc. on its proposed acquisition by Farelogix and subsequent successful acquisition by Accelya*
- Advised Amcor on its acquisition of Bemis*
- Advised Associated British Foods Plc on the acquisition by its subsidiary, Jordans & Ryvita Company Limited, of Dorset Cereals*
- Advised CAA on its acquisition of ICM Partners*
- Advised ZF Friedrichshafen on the UK aspects of a number of strategic European joint ventures*
- Advised Daimler Truck and Volvo on the UK merger control aspects of the formation of Coretura*
- Advised a UK freight logistics company in relation to both general competition law compliance and a number of key strategic initiatives*
* Denotes matters prior to joining Wilson Sonsini.
Select Publications
- Co-author, “CMA's Actions Signal New Spotlight on UK Consumer Law,” Law360, May 18, 2026
Select Publications
- Co-author, “CMA's Actions Signal New Spotlight on UK Consumer Law,” Law360, May 18, 2026
- Privacy Policy
- Terms of Use
- Accessibility